Borcherding succeeds Philipp Matthieu, who will leave Immunovia. Prior to joining Immunovia, Borcherding held various positions in the US diagnostics industry, most recently as chief marketing officer at Myriad Genetics. He will continue to lead Immunovia's US business while assuming the role of global CEO.
 
With this change, the company is simplifying and streamlining its management structure and focusing even more on commercialising IMMray™ PanCan-d, the first blood-based test for the early detection of pancreatic cancer, in the US.